Phase 2 N=10 Transplanting Hepatitis C Lungs Into Negative Lung Recipients
Lung Diseases
Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=11 Expanded Access Protocol Thymus Transplantation
Poor Thymic Function · Immunodeficiency · Athymia
Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants
Phase 1 N=4 Pancreatic Islet Cell Transplantation
Type 1 Diabetes
Primary: Achievement of Insulin Independence at 12-month Post Transplant — 1 participant
Phase 2 N=26 Thymus Transplantation in DiGeorge Syndrome #668
DiGeorge Syndrome · Complete Typical DiGeorge Anomaly
Primary: Survival at 1 Year Post-Cultured Thymus Tissue Implantation (CTTI) — 72 % of participants who survive to 1 year
Phase 4 N=2,037 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
End Stage Renal Disease (ESRD) · Chronic Kidney Disease (CKD) · Hemodialysis
Primary: Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2. — 489; 456…
Phase 2 N=3 Allogeneic Islet Cells Transplanted Onto the Omentum
Type 1 Diabetes Mellitus · Hypoglycemia · Hypoglycemia Unawareness
Primary: A1c </= 6.5% and no Severe Hypoglycemia — 0.667 Proportion of participants
Phase 2 N=62 Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients
End Stage Renal Disease
Primary: Number of Subjects Cured — 62 Participants
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
N/A N=167 Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation
End Stage Renal Disease
Primary: Number of Steps Completed in Transplant Process — 1.0; 2.8 steps per participant
Phase 2 N=64 Envarsus XR in Lung Transplant
Lung Transplant
Primary: Percentage of Patients Remaining on Envarsus XR at 1 Year — 40 Participants
Phase 2 N=14 Phase I/II Thymus Transplantation With Immunosuppression #950
DiGeorge Anomaly · Complete DiGeorge Anomaly · Complete Atypical DiGeorge Anomaly
Primary: Survival at 1 Year Post-CTTI — 71 % of participants who survive to 1 year
N/A N=72 Don't Throw Your Heart Away: Clinician Study 3
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
Phase 2 N=33 Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Phase 2 N=290 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
N/A N=29 Thymus Transplantation Safety-Efficacy
Complete DiGeorge Anomaly · DiGeorge Syndrome · DiGeorge Anomaly
Primary: Survival Rate at End of 1 Year — 79.3 percentage of participants
Phase 2 N=7 Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
Diabetes Mellitus, Type I
Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…
N/A N=320 International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation
Lung Preservation
Primary: A Composite of Patient Survival at Day 30 Post Transplantation, and Absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction…
Phase 2 N=7 Thymus Transplantation Dose in DiGeorge #932
DiGeorge Anomaly · DiGeorge Syndrome · Complete DiGeorge Anomaly
Primary: Survival at 1 Year Post-CTTI — 83 % of participants who survive to 1 year
N/A N=42 Improving Adherence in Nonadherent Kidney Transplant Patients
Medication Adherence · Kidney Transplantation
Primary: Change in Number of Patients Being Adherent/Non-aherent After the Intervention — 15; 30; 34; 35 Participants
Phase 1 N=7 Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant
Type 1 Diabetes · Type 2 Diabetes
Primary: Number of Participants Who Experienced Adverse Events — 1; 7 participants
Phase 2 N=36 Islet Transplantation for Type 1 Diabetes
Diabetes Mellitus, Insulin-Dependent
Primary: Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation. — 44; 14; 17; 14…
N/A N=416 Reducing Disparities in Living Donor Transplant Among African Americans
Kidney Transplant
Primary: Percent of Patients With at Least One Inquiry From a Potential Living Donor — 15.63; 15.63; 15.77; 15.87 percentage of participants
Phase 2 N=7 Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Diabetes Mellitus, Type 1
Primary: Insulin Independence. — 2 Participants
N/A N=2,196 Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention
Transplant
Primary: Any Hospitalization or Any Emergency Room Visits — 497; 574; 380; 391 Participants — p=<.001
Phase 2 N=25 Stem Cell Transplant w/Laronidase for Hurler
Mucopolysaccharidosis I · Hurler Syndrome
Primary: Number of Patients Alive at One Year Post Transplant — 18 Participants
Phase 4 N=30 Multi-center Study to Transplant Hepatitis-C Infected Kidneys
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Phase 1 N=2 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Kidney Failure, Chronic · Renal Insufficiency
Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Phase 2 N=25 Human Fetal Liver Cell Transplantation in Chronic Liver Failure
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
Phase 4 N=10 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants